| Sign In to gain access to subscriptions and/or personal tools. |
American Journal of Hospice and Palliative Medicine®, Vol. 24, No. 4, 264-269 (2007) DOI: 10.1177/1049909107302298 © 2007 SAGE Publications Azotemia in Cancer Patients During Inpatient RehabilitationDepartment of Palliative Care and Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Unit 08, Houston, Texas, USA, yguo{at}mdanderson.org
Department of Palliative Care and Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Unit 08, Houston, Texas, USA
Department of Palliative Care and Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Unit 08, Houston, Texas, USA
Department of Palliative Care and Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Unit 08, Houston, Texas, USA
This paper presents a study of the relationship between prerenal azotemia and rehabilitation outcomes of cancer patients. A retrospective chart review of 70 patients who underwent inpatient rehabilitation in a tertiary cancer center was undertaken. Eight patients with creatinine values >1.5 were excluded. The remaining 62 patients were divided into 2 groups according to the blood urea nitrogen/creatinine (BUN/Cr) ratio: 27 (44%) in the prerenal azotemia group (BUN/Cr
Key Words: azotemia rehabilitation cancer length of stay
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

20) and 35 (56%) in the non-azotemic group (BUN/Cr < 20). Age, gender, <10 g/dL of hemoglobin, co-morbidity (diabetes mellitus and/or hypertension), discharge destiny and median rehabilitation length of stay were not significantly different in these 2 groups. Prerenal azotemia was present in a significant number of cancer patients, but it did not impact the length of rehabilitation stay or discharge destiny.